AstraZeneca buys ZS Pharma for $2.7 billion, pips Actelion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
AstraZeneca (AZN) Reports In-Line 3Q; Leerink Partners Reiterates Market Perform
November 9, 2015 9:36 AM ESTLeerink Partners reiterated a Market Perform rating and $37.00 price target on AstraZeneca (NYSE: AZN) following the company's 3Q earnings report. Results came in relatively in line with consensus on both the top and bottom lines, with total revenue of $5.95B vs. $5.97B consensus. EPS was reported at $1.03 vs. $1.02.
Analyst Seamus Fernandez commented, "We are updating our AZN model post 3Q results, which came in... More
JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral
November 9, 2015 7:17 AM ESTJPMorgan downgraded ZS Pharma (NASDAQ: ZSPH) from Overweight to Neutral with a price target of $90.00 (from $75.00).
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $89.04 yesterday.
... MoreCredit Suisse Downgrades ZS Pharma (ZSPH) to Neutral on Takeover
November 9, 2015 6:24 AM ESTCredit Suisse downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Neutral with a price target of $90.00 (from $67.00) after the company agreed to be acquired by AZN
For an analyst ratings summary and ratings history on ZS Pharma... More
William Blair Downgrades ZS Pharma (ZSPH) to Market Perform
November 6, 2015 2:23 PM ESTWilliam Blair downgraded ZS Pharma (NASDAQ: ZSPH) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $63.31 yesterday.
... MoreRelypsa (RLYP) Poised to Open Higher Following AstraZeneca (AZN)/ZS Pharma (ZSPH) Deal
November 6, 2015 6:53 AM ESTRelypsa (NASDAQ: RLYP) shares are poised higher after AstraZeneca (NYSE: AZN) agreed to acquire ZS Pharma (NASDAQ: ZSPH) for $2.7 billion. Shares of Relypsa are set to open higher by 20%.
... MoreAstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM ESTAstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ionÂ-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition... More
